Literature DB >> 9447754

High incidence of breakthrough varicella observed in healthy Japanese children immunized with live attenuated varicella vaccine (Oka strain).

N Takayama1, M Minamitani, M Takayama.   

Abstract

In order to know the rate of occurrence of varicella among vaccinees (breakthrough varicella: BV), questionnaire postcards were sent to 593 healthy children who had received varicella vaccine (Oka strain) from March 1987 to December 1989. The questionnaire survey was repeated once a year until January 1996. The annual attack rate from the 1st to 3rd questionnaire was approximately 12%: however, from the 5th to 8th one it was 1-4%. To February 1996, the cumulative attack rate was 157/459 (34.2%). This rate was comparable to that among vaccinees who had confirmed seroconversion; namely, 51/132 (38.6%). These rates are much higher than those reported by other authors. All BV cases were clinically mild; even subjects who had received the vaccine 7 years prior to the disease showed mild symptoms. The high incidence may be partly explained by the regional epidemiology of varicella. The decrease in annual incidence with time after vaccination may be due to the following reasons: some vaccinees remained free from BV owing to reinforcement of their immunity from subclinical infection of varicella-zoster virus (VZV) and others from diminution of opportunity for exposure to VZV with increasing age. Varicella vaccine seems to be effective in modifying the symptoms of varicella, but not potent enough in protecting from VZV infection.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9447754     DOI: 10.1111/j.1442-200x.1997.tb03664.x

Source DB:  PubMed          Journal:  Acta Paediatr Jpn        ISSN: 0374-5600


  8 in total

Review 1.  Varicella vaccination--a critical review of the evidence.

Authors:  S A Skull; E E Wang
Journal:  Arch Dis Child       Date:  2001-08       Impact factor: 3.791

2.  Rapid genotyping of varicella-zoster virus vaccine and wild-type strains with fluorophore-labeled hybridization probes.

Authors:  V N Loparev; K McCaustland; B P Holloway; P R Krause; M Takayama; D S Schmid
Journal:  J Clin Microbiol       Date:  2000-12       Impact factor: 5.948

3.  Chickenpox Appearing in Previously Vaccinated Individuals.

Authors:  V Suryam; A L Das
Journal:  Med J Armed Forces India       Date:  2011-07-21

Review 4.  Preventing varicella-zoster disease.

Authors:  Sophie Hambleton; Anne A Gershon
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

Review 5.  Primary versus secondary failure after varicella vaccination: implications for interval between 2 doses.

Authors:  Paolo Bonanni; Anne Gershon; Michael Gershon; Andrea Kulcsár; Vassiliki Papaevangelou; Bernard Rentier; Catherine Sadzot-Delvaux; Vytautas Usonis; Timo Vesikari; Catherine Weil-Olivier; Peter de Winter; Peter Wutzler
Journal:  Pediatr Infect Dis J       Date:  2013-07       Impact factor: 2.129

Review 6.  Herpes simplex virus-1 and varicella-zoster virus latency in ganglia.

Authors:  Bradley M Mitchell; David C Bloom; Randall J Cohrs; Donald H Gilden; Peter G E Kennedy
Journal:  J Neurovirol       Date:  2003-04       Impact factor: 2.643

7.  Varicella-zoster virus at relapses of multiple sclerosis.

Authors:  Julio Sotelo; Graciela Ordoñez; Benjamin Pineda
Journal:  J Neurol       Date:  2007-03-31       Impact factor: 4.849

8.  Improved identification and differentiation of varicella-zoster virus (VZV) wild-type strains and an attenuated varicella vaccine strain using a VZV open reading frame 62-based PCR.

Authors:  V N Loparev; T Argaw; P R Krause; M Takayama; D S Schmid
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.